Last reviewed · How we verify
valsartan and amlodipine
Valsartan and amlodipine, marketed by Novartis, is a combination therapy currently available in the hypertension market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in generic competition following the patent expiry.
At a glance
| Generic name | valsartan and amlodipine |
|---|---|
| Also known as | valsartan-amlodipine fix combination pill |
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
- Comparing Bisoprolol and Valsartan-Amlodipine for Hypertension (PHASE4)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity (PHASE4)
- A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension (PHASE3)
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- valsartan and amlodipine CI brief — competitive landscape report
- valsartan and amlodipine updates RSS · CI watch RSS
- Novartis portfolio CI